Refrences
1. Organization, W.H. WHO Coronavirus Disease (COVID-19)
Dashboard . 2021 February 4th, 2021; Available from:
https://covid19.who.int/.
2. Shang, W., et al., The outbreak of SARS-CoV-2 pneumonia calls
for viral vaccines. npj Vaccines, 2020. 5 (1): p. 1-3.
3. Ayotte, K., J. Gerberding, and J.S. Morrison, Ending the Cycle
of Crisis and Complacency in US Global Health Security: A Report of the
CSIS Commission on Strengthening America’s Health Security . 2020:
Center for Strategic & International Studies.
4. WHO, Draft landscape of COVID-19 candidate vaccines. World
Health Organisation, 2020.
5. Cohen, J.I. and P.D. Burbelo, Reinfection with SARS-CoV-2:
Implications for Vaccines. Clinical Infectious Diseases, 2020.
6. Gudbjartsson, D.F., et al., Humoral immune response to
SARS-CoV-2 in Iceland. New England Journal of Medicine, 2020.383 (18): p. 1724-1734.
7. Crawford, K.H., et al., Dynamics of neutralizing antibody
titers in the months after SARS-CoV-2 infection. MedRxiv, 2020.
8. Dickson, M., R. Mathews, and G.G. Menon, ANALYSIS OF COVID-19
REINFECTION RATES AND ITS UNDERLYING CAUSES: A SYSTEMATIC REVIEW. 2020.
9. Krishna, E., et al., COVID-19 reinfection: Linked possibilities
and future outlook. Journal of Family Medicine and Primary Care, 2020.9 (11): p. 5445.
10. Osman, A., M. Al Daajani, and A. Alsahafi, Re-positive
coronavirus disease 2019 PCR test: could it be a reinfection? New
Microbes New Infect . 2020.
11. Plotkin, S.A., Correlates of protection induced by
vaccination. Clinical and vaccine immunology, 2010. 17 (7): p.
1055-1065.
12. Seow, J., et al., Longitudinal evaluation and decline of
antibody responses in SARS-CoV-2 infection. MedRxiv, 2020.
13. Long, Q.-X., et al., Clinical and immunological assessment of
asymptomatic SARS-CoV-2 infections. Nature medicine, 2020.26 (8): p. 1200-1204.
14. Koyama, T., D. Platt, and L. Parida, Variant analysis of
SARS-CoV-2 genomes. Bulletin of the World Health Organization, 2020.98 (7): p. 495.
15. Tillett, R.L., et al., Genomic evidence for reinfection with
SARS-CoV-2: a case study. The Lancet Infectious Diseases, 2021.21 (1): p. 52-58.
16. Prado-Vivar, B., et al., COVID-19 Re-Infection by a
Phylogenetically Distinct SARS-CoV-2 Variant, First Confirmed Event in
South America. First Confirmed Event in South America.(September 3,
2020), 2020.
17. Van Elslande, J., et al., Symptomatic SARS-CoV-2 reinfection
by a phylogenetically distinct strain. Clin Infect Dis, 2020.10 .
18. Scaria, V., Asymptomatic reinfection in two healthcare workers
from India with genetically distinct SARS-CoV-2. 2020.
19. Mo, H., et al., Longitudinal profile of antibodies against
SARS‐coronavirus in SARS patients and their clinical significance.Respirology, 2006. 11 (1): p. 49-53.
20. Payne, D.C., et al., Persistence of antibodies against Middle
East respiratory syndrome coronavirus. Emerging infectious diseases,
2016. 22 (10): p. 1824.
21. Yahav, D., et al., Definitions for coronavirus disease 2019
reinfection, relapse and PCR re-positivity. Clin Microbiol Infect,
2020.
22. Arevalo-Rodriguez, I., et al., False-negative results of
initial RT-PCR assays for COVID-19: a systematic review. PloS one,
2020. 15 (12): p. e0242958.
23. Luo, A., Positive SARS-Cov-2 test in a woman with COVID-19 at
22 days after hospital discharge: A case report. Journal of Traditional
Chinese Medical Sciences, 2020. 7 (4): p. 413-417.
24. Organization, W.H., Criteria for releasing COVID-19 patients
from isolation: scientific brief, 17 June 2020 . 2020, World Health
Organization.
25. Tao, W., et al., Re-detectable positive SARS-CoV-2 RNA tests
in patients who recovered from COVID-19 with intestinal infection.Protein & cell, 2020: p. 1-6.
26. Kang, H., et al., Retest positive for SARS‐CoV‐2 RNA of
“recovered” patients with COVID‐19: Persistence, sampling issues, or
re‐infection? Journal of medical virology, 2020. 92 (11): p.
2263-2265.
27. Chen, Y., et al., Re-evaluation of retested nucleic
acid-positive cases in recovered COVID-19 patients: Report from a
designated transfer hospital in Chongqing, China. Journal of infection
and public health, 2020. 13 (7): p. 932-934.
28. Control, C.f.D. and Prevention, Duration of isolation and
precautions for adults with COVID-19. 2020 . 2020.
29. Lu, J., et al., Clinical, immunological and virological
characterization of COVID-19 patients that test re-positive for
SARS-CoV-2 by RT-PCR. EBioMedicine, 2020. 59 : p. 102960.
30. Bonifácio, L.P., et al., Are SARS-CoV-2 reinfection and
Covid-19 recurrence possible? a case report from Brazil. Revista da
Sociedade Brasileira de Medicina Tropical, 2020. 53 .
31. Ye, G., et al., Clinical characteristics of severe acute
respiratory syndrome coronavirus 2 reactivation. Journal of Infection,
2020. 80 (5): p. e14-e17.
32. Ravioli, S., H. Ochsner, and G. Lindner, Reactivation of
COVID-19 pneumonia: a report of two cases. The Journal of infection,
2020.
33. Kang, Y.J. and H. Joo, South Korea’s COVID-19 infection
status: From the perspective of reconfirmation after complete recovery.Journal of Pure and Applied Microbiology, 2020. 14 .
34. Loconsole, D., et al., Recurrence of COVID-19 after recovery:
a case report from Italy. Infection, 2020: p. 1-3.
35. Anwar, H. and Q.U. Khan, Pathology and Therapeutics of
COVID-19: A Review. International Journal of Medical Students, 2020.8 (2): p. 113-120.
36. Xie, C., et al., False negative rate of COVID-19 is eliminated
by using nasal swab test. Travel medicine and infectious disease, 2020.
37. Zhang, D., et al., COVID‐19 infection induces readily
detectable morphologic and inflammation‐related phenotypic changes in
peripheral blood monocytes. Journal of leukocyte biology, 2020.
38. Elberry, M.H. and H. Ahmed, Occult SARS-CoV-2 infection; a
possible hypothesis for viral relapse. Medical hypotheses, 2020.144 : p. 109980.
39. Mondal, R., et al., Recurrence of COVID-19: Treading the Fine
Line Between Relapse and Re-infection. International Journal of Medical
Students, 2020. 8 (3): p. 311-313.
40. To, K.K.-W., et al., COVID-19 re-infection by a
phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole
genome sequencing. Clinical infectious diseases, 2020.
41. Chen, X., et al., Disease severity dictates
SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal
transduction and targeted therapy, 2020. 5 (1): p. 1-6.
42. Larson, D., et al., A Case of Early Re-infection with
SARS-CoV-2. Clinical infectious diseases: an official publication of
the Infectious Diseases Society of America, 2020.
43. Iwasaki, A., What reinfections mean for COVID-19. The Lancet
Infectious Diseases, 2021. 21 (1): p. 3-5.
44. Gousseff, M., et al., Clinical recurrences of COVID-19
symptoms after recovery: viral relapse, reinfection or inflammatory
rebound? Journal of Infection, 2020. 81 (5): p. 816-846.
45. Chen, Z. and E.J. Wherry, T cell responses in patients with
COVID-19. Nature Reviews Immunology, 2020. 20 (9): p. 529-536.
46. Channappanavar, R., et al., Virus-specific memory CD8 T cells
provide substantial protection from lethal severe acute respiratory
syndrome coronavirus infection. Journal of virology, 2014.88 (19): p. 11034-11044.
47. Zhao, J., et al., Antibody responses to SARS-CoV-2 in patients
with novel coronavirus disease 2019. Clinical infectious diseases,
2020. 71 (16): p. 2027-2034.
48. Liu, A., et al., Antibody responses against SARS‐CoV‐2 in
COVID‐19 patients. Journal of medical virology, 2021. 93 (1):
p. 144-148.
49. Iyer, A.S., et al., Persistence and decay of human antibody
responses to the receptor binding domain of SARS-CoV-2 spike protein in
COVID-19 patients. Science immunology, 2020. 5 (52).
50. Baumgarth, N., et al., Antibody Responses to SARS-CoV-2: Let’s
Stick to Known Knowns. The Journal of Immunology, 2020.205 (9): p. 2342-2350.
51. Amanna, I.J., N.E. Carlson, and M.K. Slifka, Duration of
humoral immunity to common viral and vaccine antigens. New England
Journal of Medicine, 2007. 357 (19): p. 1903-1915.
52. Zhang, J., et al., COVID-19 reinfection in the presence of
neutralizing antibodies. National Science Review, 2021.